A recent study found that a patented ginger extract called Ginfort, distributed by DolCas Biotech, may help relieve symptoms of dyspepsia.
A recent study published in the Journal of Dietary Supplements1 found that a patented ginger extract called Ginfort, distributed by DolCas Biotech (Landing, NJ), may help relieve symptoms of dyspepsia. Functional dyspepsia is a chronic disorder characterized by recurring signs and symptoms of indigestion. The ginger extract is standardized to 26% active gingeroid compounds such as gingerols and shagaols.
In the study, 50 subjects between the ages of 18 and 55 suffering from functional dyspepsia were randomized to receive either 200 mg of the ginger extract or placebo, twice daily for four weeks. The primary outcome assessed by researchers was overall treatment efficacy (OTE) and the secondary outcome was the elimination rate of three major symptoms (postprandial fullness, upper abdominal bloating, and early satiation) and elimination rate for each individual symptom scores. Results showed that according to the assessment of OTE, 79% of subjects taking the ginger extract were classified as responders compared to 21% of the placebo group. For the secondary outcome, the elimination rate of postprandial fullness, upper abdominal bloating, and early satiation was 64% in subjects taking the ginger extract, compared to 13% in the placebo group.
“Ginger has been revered as a food and medicine since time immemorial,” explained Shavon Jackson-Michel, ND, director of medical & scientific affairs at DolCas Biotech, in a press release. “The rhizome’s use in support of digestive health has been promising and anecdotally rewarding yet has evaded rigorous scientific evaluation in terms of producing consistently, positive results.”
Manufactured by Olene Life Sciences Ltd. Pvt. using a solvent-free extraction process, Ginfort is a powder that contains high concentrations of pure ginger polyphenols and essential oils in their native, naturally stable matrix. This enhances the stability and bioavailability of the rhizome’s particularly volatile bioactives, allowing formulators to create products with low clinical doses and less restrictive storage conditions.